BioSpace News Archive

BD, a leading global medical technology company, released findings from a survey conducted by The Harris Poll, between Nov. 14-16, 2022, among 872 U.S. women ages 18 to 64 years old, that indicate a significant gap in women’s knowledge about the primary causes of cervical cancer as well as the most effective means of prevention.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 178,100 shares, and restricted stock units covering an aggregate of 56,050 shares, of BioCryst common stock.

TScan Therapeutics, Inc. announced its 2023 clinical pipeline plans and highlighted recent corporate achievements.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, provided an update on its pipeline development programs and outlook for 2023.

BiondVax Pharmaceuticals Ltd. announced that Mr. Amir Reichman, BiondVax’s CEO will present at the Biotech Showcase conference being held Jan. 9-11, 2023.

ACELYRIN, INC. announced top-line 12-week open label data from Part A of a Phase 2b/3 trial of izokibep in patients with moderate-to-severe Hidradenitis Suppurativa.

Theseus Pharmaceuticals, Inc. announced key anticipated milestones for 2023 and introduced its third development program, a pan-variant tyrosine kinase inhibitor targeting BCR-ABL for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

The U.S. Food and Drug Administration Center for Drug Evaluation and Research has accepted the Biologics License Application for nirsevimab for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants entering or during their first RSV season and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.